Novartis Targets Next-Generation IgE Therapy With $2 Billion Excellergy Deal

According to a recent LinkedIn post from BioSpectator Inc, Novartis is pursuing a major strategic move to extend the blockbuster allergy drug Xolair franchise by agreeing to acquire early‑stage biotech Excellergy in a deal reportedly valued at about $2 billion. The post notes that this follows the failure of Novartis’s long‑developed follow‑on asset ligelizumab and rising U.S. biosimilar competition to Xolair.

The company’s LinkedIn post highlights that Excellergy, which reportedly raised $70 million in a Series A round last year, holds a Phase 1 next‑generation IgE candidate named Exl‑111. According to the post, global large pharma interest in next‑generation IgE assets remains strong, with Xolair still a central reference point, and GSK’s roughly $2.2 billion acquisition of RAPT Therapeutics cited as a comparable transaction in this emerging space.

As shared in the post, Exl‑111 is described as being inspired by Xolair but differentiated in its mechanism of action, targeting receptor‑bound IgE already attached to FcεRIα rather than focusing primarily on reducing free IgE in the bloodstream. The post emphasizes that Novartis appears to view this approach as potentially faster and more effective, underscoring a strategic bet on a distinct IgE‑modulation profile that could support future respiratory or immunology revenue streams.

The LinkedIn post further notes that Excellergy recently presented non‑clinical primate data showing near‑complete removal of membrane‑bound, receptor‑attached IgE. It also indicates that first‑in‑human dosing in a Phase 1 trial began in early February, suggesting that Novartis is moving on this acquisition at a very early development stage, with clinical risk remaining high but upside significant if safety and efficacy are confirmed.

For investors, the post suggests that Novartis is actively positioning to defend and potentially expand its IgE‑mediated disease franchise as Xolair faces biosimilar erosion, using M&A rather than internal R&D alone after ligelizumab’s failure. The referenced transactions involving Excellergy and RAPT imply that competition for differentiated IgE assets is intensifying, which could support valuations across the broader next‑generation allergy and immunology pipeline landscape.